# EDGAR Filing Document

**Accession Number:** 0000879169
**File Stem:** 0000879169-26-000046
**Filing Date:** 2026-6
**Character Count:** 5412
**Document Hash:** 01a91175c4f5ce1d06046f0837bb221a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000879169-26-000046.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0000879169-26-000046

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260622

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20260622

**DATE AS OF CHANGE**: 20260622

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INCYTE CORP
- **CENTRAL INDEX KEY:** 0000879169
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943136539
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12400
- **FILM NUMBER:** 261104873

**BUSINESS ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
- **BUSINESS PHONE:** 3024986700

**MAIL ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE CORP
- **DATE OF NAME CHANGE:** 20030318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE GENOMICS INC
- **DATE OF NAME CHANGE:** 20000710

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930902

?xml version='1.0' encoding='ASCII'? incy-20260622

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 22, 2026

**INCYTE CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-12400** | **94-3136539** |
| (State or Other Jurisdiction of<br>Incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **1801 Augustine Cut-Off**<br>**Wilmington, DE** | **19803** |
| (Address of principal executive offices) | (Zip Code) |

---

**(302) 498-6700**

(Registrant's telephone number,

including area code)

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of exchange on which registered** |
| Common Stock, $.001 par value per share | INCY | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 8.01 Other Events.**

Incyte Corporation (the "Company") today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services ("CMS") to resolve the Company's litigation related to the application of Medicaid rebate rules to Opzelura<sup>®</sup> (ruxolitinib) cream. Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi<sup>®</sup> (ruxolitinib), and the Company has withdrawn its lawsuit challenging the regulations. The settlement was reached based on the unique facts of Opzelura and Jakafi.

The Company expects to record a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026, associated with the reversal of previously established accrual balances through March 31, 2026, related to liabilities associated with the potential application of the line extension regulations to Opzelura. The Company will no longer accrue for the potential application of the line extension regulations to Opzelura and expects an improvement to Opzelura's gross-to-net on a go-forward basis. The Company plans to update financial guidance to reflect the impact of the settlement during the next scheduled earnings release.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 22, 2026 |  |  |
|  | INCYTE CORPORATION | INCYTE CORPORATION |
|  | By: | /s/ Suketu Upadhyay |
|  |  | Suketu Upadhyay |
|  |  | Executive Vice President and Chief Financial Officer |

---